Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Brain scan breakthrough could spot MS cognitive decline early

NCT ID NCT04415372

Knowledge-focused Sponsor: University of Wisconsin, Madison Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing whether a new type of MRI can detect changes in the brain that lead to memory and thinking problems in people with multiple sclerosis (MS). Researchers will scan 75 adults with MS and give them thinking and memory tests. The goal is to see if the new MRI measure, called macromolecular proton fraction, can predict who will have cognitive issues.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to better ways to detect and predict cognitive decline in MS patients using MRI.
What could go wrong
This is an observational study, not a treatment trial. It may not directly change patient care, and the new MRI method might not prove reliable enough for routine use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 75 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2021

Expected to finish

Apr 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adults diagnosed with MS both with and without evidence of cognitive impairment. Healthy controls will be recruited from the MRI Volunteer Database (2017-0004, PI: Reeder)

Ages

18 to 60 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Clinically definite MS * Adult age 18 to 60 Exclusion Criteria: * Contraindication to MRI * Changes in MS therapy in the last 6 months * Less than 6 weeks after relapse or corticosteroid use * Currently taking medication that may affect cognition (e.g. donepezil, rivastigmine, adderall) * History of significant alcohol or drug abuse * Current or recent significant migraines * Confounding neurological or cognitive disorders or deficits (stroke, Parkinson's disease, Alzheimer's disease, epilepsy) * Sensory or physical impairments that might interfere significantly with cognitive testing * History of developmental or learning disability or attention-deficit/hyperactivity disorder.\\ Exclusion Criteria for Healthy Controls: * history of alcohol/drug abuse * history of migraines * developmental or learning disability/attention-deficit/hyperactivity disorder * currently pregnant/breastfeeding

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

multiple sclerosis myeloid sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MS Multiple sclerosis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of Wisconsin, Madison

    Madison, Wisconsin, 53705, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.